Company Overview and News
VANCOUVER, British Columbia, May 23, 2018 (GLOBE NEWSWIRE) -- Panoro Minerals Ltd. (TSXV:PML) (Lima:PML) (Frankfurt:PZM) and its wholly-owned subsidiary, Panoro Trading (Cayman) Ltd. (“Panoro” or the “Company”) are pleased to announce that they have received the sixth Early Deposit payment of US$750,000 as part of the Precious Metals Purchase Agreement (the “Cotabambas Early Deposit Agreement”) with Wheaton Precious Metals International Ltd.
Although the markets have their own logic, highly capitalized gold-mining companies seemingly should belong on any “stocks to buy” list. Thanks to rising geopolitical tensions and soaring trading sentiment, many folks seek safe-haven assets. While gold stocks seemingly offer a viable solution, their overall performance has been unusually disappointing.
Royalty and streaming mining companies (RING)(SIL) have business models that are considered quite conservative because they don’t own mines. These companies have somewhat fixed income streams after making upfront payments for production rights to mines. This could be why this group of miners has seen higher valuation multiples than miners in other categories.
When it comes to precious metals, gold captures most of the spotlight. However, silver could be the real money metal in our current market. That’s because silver has the best of both worlds.
Univar Inc. (UNVR - Free Report) is slated to release first-quarter 2018 results ahead of the bell on May 10.
I don't have much to say about the markets, they are back near the highs and we'll check-in on them tomorrow,. What we do need to do is bargain-hunt in case it is a real rally and the best way to do that is to look back on past trade ideas and see if we can find some that haven't gone up yet.
The first quarter uptick in volatility to global markets presents a bullish case for gold markets.
According to metals consultancy GFMS in its latest Silver Survey, silver has now been in supply deficit for five years in a row.
It looks like the precious metals market is preparing for another leg up. If that is the case, silver should perform better than gold.
Initially, the Fed’s decision to raise the interest rate didn’t affect miners and metals much. But over the past week, both metals and miners have been choppy.
For the week, silver finished lower by 1.9% or $0.31 to close at $16.27 as of the final trade on the New York COMEX on Friday afternoon. The negative price action in silver at this juncture can only be taken as a warning sign for the entire precious metals complex moving forward: silver is acting weaker than it should at the start of an expected long-term precious metals advance. There is still a scenario by which this market could resolve higher later this year and into 2019, but it will have to prove itself in a defined manner by Q3 – Q4.
While it’s open to debate whether President Donald Trump made America great, the 2016 election did produce one undeniable result: it laid the foundation for cannabis-related businesses, thereby dramatically improving profitability potential for marijuana penny stocks.
There are a group of bankers based in three cities, not Wall St., but Toronto, Vancouver, and Denver that you probably never heard of. Surprisingly they are gold stocks. They are royalty & streaming companies, otherwise known as the Three Kings (Franco-Nevada, Royal Gold, and Wheaton Precious Metals) are the non-media grabbing bankers in the mining sector. They collect their revenue from some of the biggest mining companies in the world: Glencore, Vale, Teck Resources, Barrick Gold, Newmont Mining, AngloGold Ashanti Limited.
Silver Wheaton Corp. (NYSE:SLW) has 291 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 263,755,011 shares. Largest shareholders include Franklin Resources Inc, BlackRock Inc., Van Eck Associates Corp, First Eagle Investment Management, LLC, Carmignac Gestion, Vanguard Group Inc, FMR LLC / Fidelity, Bank Of Montreal /can/, Bank of New York Mellon Corp, and CIBC World Markets Inc.
BELIZE CITY, BELIZE / ACCESSWIRE / January 29, 2018 / GoldCrypto.io (through its Service Operator Crypto Investor, Inc.) advises as follows:
22h - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
22h - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...